Edwards Lifesciences Corporation $EW Shares Sold by Securian Asset Management Inc.

Securian Asset Management Inc. decreased its position in Edwards Lifesciences Corporation (NYSE:EW) by 1.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 30,613 shares of the medical research company’s stock after selling 544 shares during the quarter. Securian Asset Management Inc.’s holdings in Edwards Lifesciences were worth $2,394,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. Arlington Trust Co LLC lifted its holdings in shares of Edwards Lifesciences by 1.2% during the first quarter. Arlington Trust Co LLC now owns 11,092 shares of the medical research company’s stock valued at $804,000 after purchasing an additional 135 shares during the last quarter. Valeo Financial Advisors LLC lifted its holdings in shares of Edwards Lifesciences by 2.8% during the first quarter. Valeo Financial Advisors LLC now owns 5,136 shares of the medical research company’s stock valued at $372,000 after purchasing an additional 142 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its holdings in shares of Edwards Lifesciences by 0.5% during the first quarter. Allspring Global Investments Holdings LLC now owns 30,195 shares of the medical research company’s stock valued at $2,170,000 after purchasing an additional 145 shares during the last quarter. Dakota Wealth Management lifted its holdings in shares of Edwards Lifesciences by 2.5% during the second quarter. Dakota Wealth Management now owns 6,048 shares of the medical research company’s stock valued at $473,000 after purchasing an additional 146 shares during the last quarter. Finally, LRI Investments LLC lifted its holdings in shares of Edwards Lifesciences by 1.0% during the second quarter. LRI Investments LLC now owns 14,971 shares of the medical research company’s stock valued at $1,171,000 after purchasing an additional 147 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $76.03 on Wednesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. Edwards Lifesciences Corporation has a fifty-two week low of $64.89 and a fifty-two week high of $83.00. The stock’s 50-day moving average is $77.46 and its two-hundred day moving average is $76.25. The firm has a market cap of $44.64 billion, a P/E ratio of 10.94, a PEG ratio of 3.61 and a beta of 1.05.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.62 by $0.05. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. During the same period in the prior year, the firm posted $0.70 EPS. The business’s revenue was up 11.9% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

EW has been the subject of several analyst reports. Stifel Nicolaus set a $85.00 target price on Edwards Lifesciences and gave the company a “buy” rating in a report on Monday, September 22nd. Morgan Stanley upped their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 15th. Canaccord Genuity Group upped their price target on Edwards Lifesciences from $75.00 to $81.00 and gave the company a “hold” rating in a research report on Friday, July 25th. BTIG Research raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a research report on Tuesday, July 29th. Finally, Piper Sandler upped their price target on Edwards Lifesciences from $83.00 to $90.00 and gave the company an “overweight” rating in a research report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average price target of $87.06.

Insider Activity

In other news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the transaction, the insider owned 206,900 shares of the company’s stock, valued at approximately $16,150,614. This represents a 4.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Daniel J. Lippis sold 4,114 shares of the stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the transaction, the vice president directly owned 22,002 shares in the company, valued at approximately $1,748,278.92. This represents a 15.75% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.34% of the company’s stock.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.